Merck: 4-week hepatitis C treatment too short
November 10, 2014 at 18:52 PM EST
Merck hoped to trump Gilead's hepatitis C treatment with its own shorter therapy, but early results show the four-week regimen may not be successful.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.